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ABSTRACT
Background. Primary bone cancer (BC) incidence by age
has not been surveyed in Asia.
Methods. The incidence patterns of nine subtypes of pri-
mary BCs registered between 2003 and 2010 were analyzed
from Taiwan cancer registry data. More specific analyses
were conducted within age groups (Group I: 0–24 years;
Group II: 25–59 years; and Group III: 60–85? years).
Results. A total of 1,238 newly diagnosed subjects were
registered with an age-standardized incidence rate (ASR)
of 6.70 per million person-years. Overall, osteosarcoma
(OS: 45 %) was the most common, followed by chondro-
sarcoma (CS: 18 %), and Ewing sarcoma (ES: 8 %). The
percentages of cases and ASRs for age groups I, II, and III
were 36.3, 43.0, and 20.7 %, and 7.00, 5.48, and 10.28 per
million, respectively. Significant male predilections were
observed for all BCs combined, and the CS, chordoma, and
malignant ameloblastoma subtypes. Our findings demon-
strated an upward trend of 4.8 % per year over the study
period, and was more significant for females (6.7 %). A
significant increase in trend existed in the incidence of BC
among females in Group II, and the incidence of OS and
ES among females in Group I.
Conclusions. This population-based study has allowed us
to confidently define the incidence rates among three age
groups of Taiwanese. Despite overall low rates, the upward
trend in BC incidence among females may invoke a con-
cern. The results suggest areas for further study into the
underlying causes for these cancer trends.
Primary bone cancer (BC) is rare, comprising less than
1 % of all cancers; however, it is the seventh most common
type of cancer among children and adolescents, repre-
senting 5 % of cancers in those aged 0–19 years.1 Previous
studies from Western countries have indicated significant
differences in the incidence of BC subtypes among dif-
ferent ethnic groups.2–5 Because the incidence of BC is
clearly age-dependent, the incidence of BC analyzed by
age groups would be more meaningful.2,5 A study on
worldwide osteosarcoma (OS) incidence patterns revealed
that incidence rates were similar in the younger age groups,
while the greatest variation was observed in the elderly. To
our knowledge, reliable data on the incidence in elderly
patients of some Asian countries is lacking.5 A previous
report on the cancer trends in Taiwan showed the incidence
of BC was based on the population of all ages combined,
but without data by age groups.6
Most studies investigating pediatric groups enrolled patients
aged 0–18 years; however, primary BCs were not only com-
mon in adolescents (15–19 years) but also in young adults (20–
24 years), and usually they share common treatment strategies
in both age groups. Surveillance of cancer incidence in this
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neglected age group of young adults would raise awareness
about primary BC. The current study was based on the popu-
lation-based data from the Taiwan cancer registry (TCR) and
aimed to broaden the availability and comparability of data and
characterization of BC incidence in all age groups. Three age
groups (0–24, 25–59, and 60–85? years) were categorized to
focus on the two incidence peaks in children/adolescents and
the elderly, as well as the incidence plateau among subjects
aged 25–59 years as described previously.2,5 Moreover,
because up to 98 % of the population (23 million) of Taiwan are
Han Chinese,7 the results from this study will provide further
insights into the comparisons of other Chinese ethnic groups
with populations from Western countries.
MATERIALS AND METHODS
Data Collection
Incidence data were obtained from the TCR, which is
organized and funded by the Health Promotion Adminis-
tration, Ministry of Health and Welfare, Taiwan. The TCR is
population-based and began data collection in 1979. Tai-
wan’s National Health Insurance program was first launched
in 1995, which is a mandatory universal health insurance
program with a coverage rate of up to 99 %. Furthermore, in
accordance with the enactment of the Cancer Control Act in
2003, hospitals with a capacity of more than 50 beds were
mandated to submit cancer data to the central cancer registry,
which enhanced the completeness of case ascertainment and
improved the quality of cancer data collection.6,8 In terms of
data quality of the TCR according to the indicators defined by
the International Agency for Research on Cancer of the
World Health Organization, the percentage of ‘death cer-
tificate only’ cases fell from 2.66 % in 2003 to 0.85 % in
2010.8 The percentage of microscopically verified cases
(MV%) is another indicator presenting data validity; despite
varying by the types of cancer, the percentage was 91.1 % in
2010 for all cancers combined. The above indicators reveal
the high quality of the registry, with remarkable improve-
ment over time.
Primary BCs were classified according to the Interna-
tional classification of diseases for oncology, third edition
(ICD-O-3: C40–C41).9 Subgroups of primary BCs were
defined by the TCR as ‘osteosarcoma’, ‘chondrosarcoma
(CS)’, ‘malignant giant cell tumor (GCT)’, ‘Ewing sarcoma
(ES)’, ‘chordoma’, ‘malignant ameloblastoma’, ‘other
specified sarcoma (including fibrosarcoma, synovial sar-
coma, hemangiosarcoma, neurofibrosarcoma, etc.)’,
‘sarcoma, not otherwise specified (NOS: including undif-
ferentiated sarcoma and malignant tumor, fusiform cell type,
etc.)’, and ‘other malignancy (including carcinomas and
other non-sarcoma neoplasms)’. Lymphoma and multiple
myeloma were not included in the current study.
Analyses
Age-standardized incidence rates (ASRs) were expressed
per million person-years by gender, and presented according
to the nine subgroups, as defined above. Rates, cumulative
risk, standard errors, and 95 % confidence intervals (CIs)
were calculated by the methods published previously.10 Age-
specific rates were stratified into the following eighteen 5-
year age groups: 0–4, 5–9, 10–14, 15–19, 20–24, …, and
85?. ASRs were computed by the direct method of stan-
dardization according to the 2000 world standard population
for 5-year age groups.10 More specific comparison of the
ASRs among the three age groups (Group I: 0–24 years;
Group II: 25–59 years; and Group III: 60–85? years) were
performed. Male-to-female standardized rate ratios (M/F
SRRs) and 95 % CIs were calculated by histologic subtypes
for the three age groups.10 The rates were considered to be
significantly different at the 5 % level when the estimated
95 % CI did not contain 1. The results of quality indicators,
including the MV% by subtypes, were also analyzed. Trend
analyses were calculated by the Joinpoint regression model,
and permutation tests were used to determine the signifi-
cance level (Joinpoint Regression Program, Version
4.0.4).11 Results were expressed as the average annual per-
cent change (AAPC). The AAPC was considered significant
if the 95 % CI did not include zero.
RESULTS
A total of 1,238 subjects were diagnosed with primary
BCs between 2003 and 2010, giving a crude rate of 6.78
and ASR of 6.70 per million person-years, respectively
(Table 1). Primary BCs comprised 0.2 % of all cancers.
The median age of patients at diagnosis was 39 years. The
cumulative risk of developing primary BC from birth to
age 74 years was 0.05 %. OS was the most common BC
subtype, accounting for 45 %, followed by CS (18 %) and
ES (8 %). The three subtypes comprised approximately
70 % of primary BCs. Overall, the MV% for primary BCs
was 96.0 %. The MV% varied from 97.5 to 100 % for all
BC subtypes with the exception of ‘other malignancy’, in
which the MV% only accounted for 29.8 %.
Age-Specific Incidence Rates by Histologic Subtype
The incidence of primary BCs revealed a bimodal distri-
bution, with a primary peak during the second decade of life
and a secondary peak amongst the elderly (Fig. 1a). The
incidence patterns of OS and ES were similar and were more
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common for children and adolescents. OS peaked at 10–
19 years of age for both genders, while ES peaked earlier,
especially for females (5–9 years of age; Fig. 1b, d). The
incidence of CS steadily increased with age (Fig. 1c).
Malignant GCT was more common in middle-aged and
elderly patients (Fig. 1e). Chordoma and malignant amelo-
blastoma mainly affected elderly individuals (Fig. 1f, g).
Relative Rate of Histologic Subtypes in Age Groups I,
II, and III
Patients with primary BCs accounted for 36.3, 43.0,
and 20.7 % for age groups I, II, and III, respectively
(Table 1). There were 449 patients with an ASR of 7.00
per million in Group I (Table 1). OS was the most
common subtype, comprising two-thirds of the patients,
and ES was the second most common subtype (13 %),
followed by CS (6 %). Other specified sarcomas
accounted for 10 % of the primary BCs. All other sub-
types were rare.
Group II comprised of 533 patients, with an ASR of 5.48
per million. Together, OS (30 %) and CS (29 %) accounted
for approximately 60 % of primary BCs and were the most
common subtypes. Chordoma was the third most common
subtype (9 %). ES, malignant GCT, and malignant amelo-
blastoma were rare.
Group III comprised of 256 patients, with an ASR of
10.28 per million. OS and CS were the most common
primary BCs and the rates were similar (24–23 %,
respectively). As with Group II, chordoma was also the
third most common subtype and accounted for 11 % of
primary BCs.
TABLE 1 Incidence of primary bone cancer by age group, gender, and histologic subtype, Taiwan (2003–2010)
Histologic subtype Gender Age group (years)
I: 0–24 II: 25–59 III: C60 All ages
No. ASRa 95 % CI No. ASRa 95 % CI No. ASRa 95 % CI No. ASRa 95 % CI
Osteosarcoma All persons 300 4.61 4.09–5.14 160 1.66 1.41–1.92 59 2.41 1.79–3.03 519 3.01 2.75–3.28
Males 173 5.17 4.39–5.94 74 1.52 1.17–1.86 29 2.27 1.43–3.10 276 3.17 2.79–3.55
Females 127 4.17 3.44–4.89 86 1.75 1.38–2.13 30 2.39 1.53–3.25 243 2.86 2.49–3.23
Chondrosarcoma All persons 30 0.45 0.28–0.61 155 1.60 1.35–1.85 59 2.37 1.76–2.99 244 1.20 1.05–1.35
Males 21 0.63 0.36–0.90 85 1.72 1.35–2.08 31 2.43 1.56–3.30 137 1.34 1.11–1.56
Females 9 0.27 0.09–0.44 70 1.42 1.08–1.75 28 2.19 1.37–3.01 107 1.02 0.82–1.21
Ewing sarcoma All persons 54 0.89 0.65–1.13 25 0.26 0.16–0.36 4 0.16 0.00–0.32 83 0.52 0.40–0.63
Males 34 1.09 0.72–1.46 13 0.26 0.12–0.40 1 0.06 -0.06 to 0.19 48 0.59 0.42–0.76
Females 20 0.72 0.40–1.04 12 0.25 0.11–0.39 3 0.24 -0.03 to 0.51 35 0.45 0.29–0.60
Malignant giant cell tumor All persons 6 0.09 0.02–0.16 24 0.25 0.15–0.36 10 0.44 0.17–0.72 40 0.20 0.14–0.27
Males 2 0.06 -0.02 to 0.13 12 0.25 0.11–0.40 6 0.54 0.11–0.97 20 0.20 0.11–0.29
Females 4 0.12 0.00–0.24 12 0.25 0.11–0.39 4 0.33 0.00–0.66 20 0.21 0.11–0.30
Chordoma All persons 6 0.09 0.02–0.16 48 0.48 0.34–0.62 29 1.17 0.74–1.60 83 0.40 0.31–0.48
Males 4 0.12 0.00–0.24 32 0.64 0.41–0.86 20 1.54 0.85–2.23 56 0.52 0.38–0.66
Females 2 0.06 -0.02 to 0.15 16 0.30 0.15–0.45 9 0.73 0.25–1.21 27 0.25 0.15–0.35
Malignant ameloblastoma All persons 3 0.05 -0.01 to 0.10 16 0.16 0.08–0.25 10 0.41 0.15–0.67 29 0.14 0.09–0.20
Males 2 0.06 -0.02 to 0.15 12 0.24 0.10–0.37 8 0.66 0.20–1.12 22 0.21 0.12–0.30
Females 1 0.03 -0.03 to 0.09 4 0.09 0.00–0.17 2 0.16 -0.06 to 0.37 7 0.07 0.02–0.12
Other specified sarcoma All persons 42 0.70 0.48–0.91 70 0.71 0.54–0.88 45 1.79 1.26–2.32 157 0.83 0.70–0.97
Males 26 0.83 0.50–1.15 39 0.76 0.52–1.00 18 1.42 0.76–2.09 83 0.87 0.68–1.06
Females 16 0.59 0.30–0.89 31 0.63 0.41–0.85 27 2.06 1.28–2.84 74 0.78 0.60–0.97
Sarcoma, NOS All persons 4 0.07 0.00–0.13 17 0.17 0.09–0.25 15 0.57 0.28–0.87 36 0.17 0.12–0.23
Males 2 0.07 -0.03 to 0.17 11 0.22 0.09–0.34 5 0.37 0.04–0.70 18 0.17 0.09–0.25
Females 2 0.06 -0.02 to 0.15 6 0.12 0.02–0.21 10 0.75 0.28–1.22 18 0.17 0.09–0.25
Other malignancy All persons 4 0.06 0.00–0.13 18 0.18 0.10–0.27 25 0.95 0.58–1.33 47 0.22 0.16–0.29
Males 3 0.10 -0.02 to 0.22 11 0.23 0.09–0.36 13 0.91 0.41–1.41 27 0.25 0.16–0.35
Females 1 0.03 -0.03 to 0.08 7 0.13 0.03–0.23 12 0.89 0.38–1.40 20 0.18 0.10–0.26
All types All persons 449 7.00 6.35–7.65 533 5.48 5.02–5.95 256 10.28 9.01–11.55 1,238 6.70 6.32–7.08
Males 267 8.12 7.13–9.10 289 5.83 5.15–6.50 131 10.20 8.42–11.97 687 7.33 6.77–7.89
Females 182 6.05 5.17–6.94 244 4.94 4.31–5.56 125 9.74 8.02–11.46 551 5.99 5.47–6.50
ASRs age-standardized incidence rates, CI confidence interval, NOS not otherwise specified
a ASRs were per million person-years and were age-standardized to the 2000 world standard population













































































































































































FIG. 1 Age-specific incidence
rates by histologic subtypes and
gender for primary bone cancers
in Taiwan (2003–2010)
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Male-to-Female Standardized Rate Ratios by
Histologic Subtype in Age Groups I, II, and III
For all age groups combined, males were more likely to be
diagnosed with primary BCs than females (M/F SRR 1.22;
Table 2). There was a significant male predilection in some
subtypes, including CS, chordoma, and malignant amelo-
blastoma, with M/F SRRs ranging from 1.31 to 2.98.
Malignant GCT was the only subtype in which the M/F SRR
was\1; however, this result was not statistically significant.
A significant male predominance was apparent in Group
I when all patients were combined, with a M/F SRR of
1.34. In the subtypes of BCs, only CS exhibited a signifi-
cant male predominance (M/F SRR 2.33).
While incidence rates for all patients of subtypes in
Groups II and III combined, no statistical difference was
detected between genders, except chordomas in Group II
with male predominance (M/F SRR 2.11).
Temporal Trends
Figure 2 illustrates the temporal trends in the incidence
rates by age groups during the study period. Table 3
demonstrates the AAPC in incidence rates by age group,
histologic subtype, and gender during 2006–2010. For all
age groups combined, the AAPC of all BCs was 4.8 % with
statistical significance, and was more significant for
females (AAPC 6.7 %). Furthermore, the incidence rates
rose significantly in subtypes of OS, ES, and sarcoma NOS
(AAPC 5.5–43.0 %).
For all persons combined among the three age groups,
only the incidence rates of Groups II and III rose signifi-
cantly (AAPC 7.4 and 6.4 %, respectively). Significant
increasing trend was only found in females of Group II.
For the subtypes among the three age groups, only the
incidence rates of CS in Group III rose significantly (AAPC
8.2 %); in contrast, it declined significantly for other
specified sarcoma in Group I (AAPC -17.4 %).
Accounting for genders, the incidence rate rose most sig-
nificantly for females with OS and ES in Group I (AAPC
14.0 and 14.6 %, respectively).
DISCUSSION
This is the first report documenting the incidence of
primary BC in three age groups in Asia. The overall age-
specific incidence patterns reported in this study were
consistent with those reported in Western countries,2,3,12–20
showing that OS and ES are more likely to be diagnosed in
youth, whereas CS and GCT occur more frequently in
middle-aged and elderly individuals, and chordomas and
ameloblastomas predominantly affect elderly patients.
However, more details remain to be clarified.
The ASR of OS was 3.01 per million in the current study
(Table 1), which is consistent with the findings in the
previous large-scale studies.3,12–14 Further comparison of
the incidences of BCs in the three age groups showed that
the greatest variation in incidence was observed in the
elderly and was markedly lower than the world average
(2.27 and 2.39 vs. 4.6 and 3.3 per million for males and
females, respectively).5 This finding has been reported to
be associated with a lower risk of Paget’s disease (which
resulted in secondary transformation into OS in the elderly)
among Asians compared with Caucasian Americans.2,4,5
Vitamin D deficiency may also have a role involving the
lower incidence in elderly Asians.5 As vitamin D defi-
ciency has been associated with the risk of developing
colon, prostate, breast, and several other cancers,21,22 it is
theoretically possible that abundant sunshine in Taiwan
along with adequate intake of vitamin D in the elderly may
contribute to the reduced risk of OS.5,23
The incidence of CS reported is approximately 2–3 per
million, and most literature indicates that racial differences
are not significant.3,12,13 In contrast, other researchers have
concluded that the relative frequency of CS is higher
among Americans than Asians.4 Our observation based on
the 244 cases of CS were consistent with the latter findings.
Specifically, we found the ASR was only 1.20 per million
and was similar to the results in China and Japan (0–1 per
million),4,14 but much lower than that in the US (2.4–2.7
and 1.6–2.7 for males and females, respectively)3 and
England (1.7–2.0 per million).12
Racial disparities in incidence were also evident for
ES.4,15 The most striking example was from the US, which
showed that there was up to a ninefold difference between
black and white (ASR 0.17 vs. 1.55 per million).15 Simi-
larly, the ASR of ES was only 0.52 per million in our
findings, which was consistent with the results from China
(0–1 per million),14 but 2- to 3-fold lower than the US and
England.3,12
Studies reporting the incidence of malignant GCTs of
bone were limited. Based on the analysis of 40 cases in the
current study, the ASR was 0.20 per million in Taiwan
(Table 1), thus comprising 3 % of all malignant BCs.
Indeed, the incidence was slightly higher than previously
reported in the US (0.16 per million).17 Notably, a higher
incidence of GCTs in the Chinese population has been
reported, ranging from 13.7 to 20 % of all bone tumors
(benign and malignant).16,18 In contrast, the incidence was
only 5 % in other large-scale studies.16–18 When compared
with all GCTs that most frequently occur in persons aged
20–40 years,16 malignant GCTs in the current study were
more likely to occur in the elderly, and the incidence was
consistent with previous reports that showed no gender
predilection.17 However, a limitation of the study that the
data from TCR included ‘malignant’ GCTs only should be
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borne in mind because the distribution of malignant GCTs
across age groups remains unknown.
The annual incidence of chordomas in the US is 0.80–
0.84 per million.19,20 The occurrence of chordomas is rare
among African Americans compared with Caucasians in
the US,19 and has been considered to have racial dispari-
ties. Based on the analysis of 83 extracranial chordomas,
the incidence patterns demonstrated herein did not reveal
TABLE 2 Male-to-female SRR by histologic subtype among three age groups for primary bone cancer, Taiwan (2003–2010)
Histologic subtype Age group (years)
I: 0–24 II: 25–59 III: C60 All ages
SRR 95 % CI SRR 95 % CI SRR 95 % CI SRR 95 % CI
Osteosarcoma 1.24 0.99–1.56 0.86 0.63–1.18 0.95 0.57–1.59 1.11 0.93–1.32
Chondrosarcoma 2.33* 1.09–5.01 1.21 0.88–1.66 1.11 0.66–1.86 1.31* 1.02–1.69
Ewing sarcoma 1.51 0.87–2.62 1.04 0.47–2.29 0.27 0.03–2.56 1.32 0.84–2.06
Malignant giant cell tumor 0.46 0.09–2.48 1.01 0.45–2.24 1.63 0.46–5.81 0.99 0.53–1.84
Chordoma 1.98 0.37–10.49 2.11* 1.16–3.81 2.11 0.97–4.56 2.09* 1.33–3.30
Malignant ameloblastoma 1.90 0.18–19.75 2.77 0.95–8.05 4.21 0.97–18.16 2.98* 1.32–6.69
Other specified sarcoma 1.39 0.75–2.60 1.22 0.76–1.95 0.69 0.38–1.26 1.11 0.80–1.54
Sarcoma, NOS 1.11 0.15–8.18 1.82 0.68–4.87 0.49 0.17–1.42 1.01 0.52–1.97
Other malignancy 3.59 0.37–34.85 1.75 0.68–4.53 1.02 0.46–2.24 1.43 0.79–2.59
All types 1.34* 1.11–1.62 1.18 1.00–1.40 1.05 0.82–1.34 1.22* 1.09–1.37
SRR standardized rate ratio, CI confidence interval, NOS not otherwise specified
* Indicates statistical significance at the 0.05 level
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evidence of variations compared with Western coun-
tries.12–14,19,20 The ASR was 0.40 per million, with a
pronounced male predilection.
Our study showed an increasing trend in the incidence of
BC among females in Group II, and the incidences of OS
and ES among females in Group I (Table 3). A strong
association between growth spurts of children and adoles-
cents and the development of OS is well known. However,
this condition was not applicable for interpreting the
observation for Group II. Many authors indicated that the
incidence of certain types of female cancers were influenced
by reproductive factors.24,25 The number of babies who
were born to females aged 15–49 years (childbearing years)
has been decreasing over the study period in Taiwan, with a
total fertility rate of only 0.895 in 2010 (the lowest in the
world).26 In which, first pregnancy at older age and more
women receiving fertility treatment were also found.27
Another issue that may need more attention is the use of
traditional Chinese medicine in the pediatric population for
helping grow and treat musculoskeletal injury in Taiwan,28
because the long-term influence on health and efficacy has
never been well studied. Furthermore, more Taiwanese
children are raised on the incorporation of a Westernized
diet and dietary factors are thought to account for approx-
imately 30 % of cancers in Western countries.29,30
Additional investigations are warranted to clarify the
TABLE 3 AAPC in incidence rates by histologic subtype and gender, primary bone cancer, Taiwan (2006–2010)
Histologic subtype Gender Age group (years)
I: 0–24 II: 25–59 III: C60 All ages
AAPCa 95 % CI AAPCa 95 % CI AAPCa 95 % CI AAPCa 95 % CI
Osteosarcoma All persons 3.3 -0.5 to 7.2 4.9 -1.4 to 11.6 7.3 -6.9 to 23.8 5.5* 4.2–6.9
Males 4.6* 0.9–8.4 -4.7 -11.2 to 2.3 3.1 -11.1 to 19.5 0.9 -2.0 to 4.0
Females 14.0* 7.6–20.7 7.5 -2.9 to 19.0 – 9.4* 4.7–14.2
Chondrosarcoma All persons -5.5 -21.3 to 13.6 8.3 -2.1 to 19.7 8.2* 0.9–16.1 6.0 -2.2 to 14.9
Males – 3.0 -7.7 to 14.9 8.7 -6.2 to 26.0 5.7 -2.4 to 14.6
Females – 6.8 -6.4 to 21.9 -2.9 -17.8 to 14.7 4.4 -6.1 to 16.1
Ewing sarcoma All persons 4.5 -12.8 to 25.2 – – 43.0* 40.1–45.9
Males – – – –
Females 14.6* 0–31.4 – – 14.4 -0.3 to 31.3
Malignant giant cell tumor All persons – – – 4.5 -17.4 to 32.2
Males – – – 5.0 -20.1 to 38.0
Females – – – –
Chordoma All persons – 2.2 -8.3 to 14.0 -5.3 -19.8 to 11.9 -1.5 -13.0 to 11.5
Males – 2.6 -9.3 to 16.0 -7.0 -23.0 to 12.4 0.9 -10.2 to 13.4
Females – -11.3 -27.6 to 8.7 – -7.3 -23.9 to 12.7
Malignant ameloblastoma All persons – – – -5.9 -23.7 to 16.2
Males – – – –
Females – – – –
Other specified sarcoma All persons -17.4* -30.5 to -1.8 7.2 -8.5 to 25.5 15.5 -7.2 to 43.6 1.6 -8.2 to 12.5
Males -4.2 -20.6 to 15.6 -16.5 -35.7 to 8.4 9.0 -11.8 to 34.7 3.4 -5.8 to 13.5
Females – 2.1 -13.6 to 20.5 – -1.9 -12.7 to 10.2
Sarcoma, NOS All persons – – – 10.1* 4.3–16.1
Males – – – 14.4* 0.5–30.1
Females – – – 6.1 -7.3 to 21.5
Other malignancy All persons – – 10.1 -9.8 to 34.5 8.3 -4.1 to 22.3
Males – – -5.1 -28.1 to 25.2 4.5 -7.7 to 18.4
Females – – – 12.0 -2.6 to 28.9
All types All persons 0.6 -3.5 to 4.8 7.4* 0.6–14.6 6.4* 2.4–10.5 4.8* 0.3–9.4
Males -1.0 -4.8 to 2.9 5.4 -4.2 to 16.0 5.1 -3.5 to 14.3 3.2 -2.5 to 9.1
Females 3.0 -3.5 to 9.9 9.4* 3.6–15.5 7.4 -0.5 to 15.9 6.7* 2.5–11.2
AAPC average annual percent change, CI confidence interval, NOS not otherwise specified, ‘‘–’’ indicates calculation of the APC was precluded by at least 1 annual
rate of zero
a The AAPC was calculated via weighted least-squares regression
* Indicates statistical significance at the 0.05 level
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association between reproductive and diet/environmental
factors and risk for BC among females in Group II, and the
risk for OS and ES among females in Group I.
There were limitations in this study. First, the reliability
of the study may be challenged by a small number of BC
subtype cases other than OS, CS, and ES, especially when
they were divided into three age groups. Second, some
specific diagnostic dilemmas for primary BCs existed, such
as CS was notoriously hard to be diagnosed histologically,
benign cartilage lesions can be difficult to differentiate
from slow-growing and low-grade CS, and giant cell-rich
OS may focally closely mimic malignant GCT. Third, the
upward trend in the incidence among females should also
be interpreted cautiously because of the number of cancers
categorized into ‘other specified sarcoma’ was corre-
spondingly decreased (AAPC -17.4 %, Group I; Table 3)
as the diagnostic accuracy increased. We could not rule out
the possibility that an increased level of diagnostic speci-
ficity led to a relative increase in the proportion of certain
subtype in the same age group. Fourth, the completeness of
cancer registration, as the DCO% fell from 2.66 % in 2003
to 0.85 % in 2010 (indicating a 1.8 % increase of the
registration completeness during the 8-year study period),
may have partly contributed to the increasing trend. Fur-
thermore, the incidence data of Chinese available for
comparison in the current study were from different reg-
istries in China,14 and with a wide variation in MV%
(49.8 % [Shanghai] to 97.2 % [Zhongshan] for primary
BCs). As a result, the accuracy in judgments of the inci-
dence variations between countries has been limited.
CONCLUSION
The estimates of primary BC incidence rates among
three age groups presented herein were based, for the first
time, on high-quality national registration data in Taiwan.
Our study demonstrates distinct differences in distribution
of BC subtypes and incidence among three age groups. We
have confirmed some historic findings from other series
that indicated significant variations in primary BC inci-
dence according to age, gender, and race. The results of
this study may lay the groundwork for generating further
research hypotheses into causes of these cancers.
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